BioVex Initiates Phase 1 Clinical Trial With Its Genital Herpes Vaccine, ImmunoVEXHSV2
March 8, 2010 – 7:21 amBioVex Inc, a private biotechnology company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announced that the first subject had been dosed in the Phase 1 study of its live attenuated genital herpes vaccine, ImmunoVEXHSV2. The Phase 1 study is an open label ascending dose trial, assessing safety and immune response in healthy volunteers. The study is taking place in the UK at the Chelsea and Westminster Hospital in London and will involve up to 42 already identified subjects. The principle investigator is Dr. Simon Barton…
Related Info :
Tags: Biologics, BioVex, Chelsea And Westminster Hospital, Clinical, Clinical Trial, Dr Simon, Genital, Genital Herpes, Genital Herpes Vaccine, Herpes, Herpes 1, Immune Response, ImmunoVEXHSV2, Infectious Disease, Initiates, London, New Generation, Phase, Prevention, Principle Investigator, Private Biotechnology Company, Simon Barton, Treatment Of Cancer, Trial, vaccine, Volunteers
One Response to “BioVex Initiates Phase 1 Clinical Trial With Its Genital Herpes Vaccine, ImmunoVEXHSV2”
Youre so cool! I dont suppose Ive read anything like this before. So good to seek out any person with some original thoughts on this subject. realy thanks for beginning this up. this web site is something that is needed on the net, somebody with a bit of originality. helpful job for bringing something new to the web!
By Argentina Daughtery on Dec 17, 2011